Aberrant expression of chromogranin A, miR-146a,and miR-146b-5p in prostate structures with focally disrupted basal cell layers: An early sign of invasion and hormone-refractory cancer?

Cancer Genomics and Proteomics

Volumn 8, Issue 5, 2011, Pages 235-244

  Man, Yan Gao ^a   Fu, S W ^b   Liu, A J ^c   Stojadinovic, A ^d   Izadjoo, M J ^a   Chen, L ^b   Gardner, W A ^e  

^a Henry Jackson Foundation   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Basal cells; Chromogranin A; miRNA; Prostate cancer; Tumor progression

Indexed keywords

CHROMOGRANIN A; MICRORNA; MICRORNA 146A; MICRORNA 146B 5P; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL; CANCER INVASION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 80054680434     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Carruba G, Stefano R and Cocciaeliferro L: Intercellular communication and human prostate carcinogenesis. Ann NY Acad Sci 963: 156-168, 2002. (Pubitemid 34721708)
2. Goldstein NS, Underhiel J, Roszka N and Neill JS: Cytokeratin 34 beta E-12 immunoreactivity in benign prostate acini. Quantitation, pattern assessment, and electron microscopic study. Am J Clin Pathol 112: 69-74, 1999. (Pubitemid 30214738)
3. Bonkhoff H, Wernert N, Dhom G and Remberger K: Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 418: 375-381, 1991.
4. Kosir MA, Wang W, Zukowski KL and Tromp G: Degradation of basement membrane by prostate tumor heparanase. J Surg Res 81: 42-47, 1999. (Pubitemid 29393775)
5. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F and Loda M: p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-1775, 2000.
6. Kurita T, Medina RT, Mills AA and Cunha GR: Role of p63 and basal cells in prostate. Development 131: 4955-4964, 2004. (Pubitemid 39485353)
7. Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I: Maspin expression profile in human prostate cancer (caP) and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res 8: 1172-1177, 2002. (Pubitemid 34517655)
8. Cher ML, Biliran HR jr, Bhangat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M and Sheng S: Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in animal model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 100: 7847-7852, 2003. (Pubitemid 36760058)
9. Man YG, Shen T, Zhao YG and Sang QXA: Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer degradations and tumor invasion. Cancer Detect Prev 29: 161-169, 2005.
10. Man YG, Zhao CQ, Wang J and XL Chen: A subset of prostate basal cells lacks corresponding phenotypic markers. Pathol Res Pract 202: 651-662, 2006.
11. Man YG and Gardner WA: Focal degeneration of basal cells and the resultant auto-immunoreactions:a novel mechanism for prostate tumor progression and invasion. Med Hypoth 70: 387-408, 2008.
12. Man YG and Gardner WA: Bad seeds produce bad crops: a single step-process of prostate carcinogenesis and Progression. Int J Biol Sci 4: 246-258, 2008.
13. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M and Doki Y: Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 115: 3324-3334, 2009.
14. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D and Sheahan K: Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 33: 134-141, 2009.
15. Hart IR: New evidence for tumor embolism as a model of metastasis. J Pathol 219: 275-276, 2009.
16. Ather MH, Abbas F, Faruqui N, Israr M and Pervez S: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 8: 21-25, 2008.
17. Autorino R, Lamendola MG, De Luca G, De Sio M, Giuliano F, D' Armiento M, De Placido S,Conti P and Di Lorenzo G: Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer. Int J Immunopathol Pharmacol 20: 765-770, 2007.
18. Hirano D, Minei S, Sugimoto S, Yamaguchi K, Yoshikawa T, Hachiya T, Kawata N, Yoshida T and Takahashi S: Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol 41: 297-301, 2007. (Pubitemid 47357194)
19. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa RM and Dogliotti L: Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone-refractory disease. J Urol 178: 838-843, 2007. (Pubitemid 47211059)
20. Grimaldi F, Valotto C, Barbina G, Visentini D, Trianni A, Cerruto MA and Zattoni F: The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer. Int J Biol Markers 21: 229-234, 2006. (Pubitemid 46165214)
21. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A and Dogliotti L: Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12: 109-117, 2005. (Pubitemid 40477092)
22. Bonkhoff H: Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 12(Suppl 2): S141-144, 2001.
23. Li Y, Chen HQ, Chen MF, Liu HZ, Dai YQ, Lv H, Bing Zu X and Qi L: Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Life Sci 84: 882-887, 2009.
24. Fu SW, Chen L and Man YG: miRNA Biomarkers in breast cancer detection and management. J Cancer 2: 116-122, 2011.
25. Man YG and Burgar A: An antigen unmasking protocol that satisfies both immunohistochemical and subsequent molecular biological assessments. Pathol-Res Pract 199: 815-825, 2003.
26. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, Bouzyk M, Sledge GW Jr, Moreno CS and Leyland-Jones B: Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 44: 417-423, 2008. (Pubitemid 351498195)
27. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high-density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003. (Pubitemid 36181903)
28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
29. Lopez-Romero P, González MA, Callejas S, Dopazo A and Irizarry RA: Processing of Agilent microRNA array data. BMC Res Notes 3: 18-23, 2010.
30. Fendler A, Stephan C, Yousef GM and Jung K: MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem 57(7): 954-968, 2011.
31. http://diana.cslab.ece.ntua.gr/microT
32. http://www.microma.org/microma/home.do
33. Bonkhoff H and Remberger K: Morphogenesis of benign prostatic hyperplasia and prostatic carcinoma. Pathologe 19: 12-20, 1998. (Pubitemid 28109257)
34. Bostwick DG: Prospective origins of prostate carcinoma. Prostate intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78: 330-336, 1996.
35. Haggman MJ, Macoska JA, Wojno KJ and Oesterling JE: The relationship between prostate intraepithelial neoplasia and prostate cancer: critical issues. J Urol 58: 12-22, 1997. (Pubitemid 27251585)
36. DeMarzo AM, Nelson WG, Isaacs WB and Epstein JI: Pathological and molecular aspects of prostate cancer. Lancet 361: 955-964, 2003. (Pubitemid 36332115)
37. Bonkhoff H and Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28: 98-106, 1996. (Pubitemid 26066247)
38. Webber MM, Waghray A and Bello D: Prostate-specific antigen, a serine protease, facilitates human cancer cell invasion. Clin Cancer Res 1: 1089-1094, 1995.
39. Barsky SH, Siegal GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by the benign counterparts. Lab Invest 49: 140-147, 1983. (Pubitemid 13039938)
40. Gardner WA and Culberson DE: Atrophy and proliferation in the young adult Prostate. J Urol 137: 53-56, 1987. (Pubitemid 17214223)
41. Gardner WA: Hypothesis: Pediatric Origins of Prostate Cancer. Hum Path 26: 1291-1292, 1995.
42. Bennett BD and Gardner WA: Embryonal hyperplasia of the prostate. The Prostate 7: 411-417, 1985. (Pubitemid 16200202)
43. Malins DC, Polissar NL, Su Y, Gardner HS and Gunselman SJ: A new structural analysis of DNA using statistical models of infrared spectra. Nat Med 3: 927-930, 1997.
44. Malins DC, Johnson PM and Barker EA: Cancer-related changes in prostate DNA as men age and early identification of metastasis in prostate tumors. Proc Natl Acad Sci USA 100: 5401-5406, 2003. (Pubitemid 36542717)
45. Malins DC, Anderson KM and Gilman NK: Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci USA 101: 10721-10725, 2004. (Pubitemid 38955809)
46. Malins DC, Gilman NK and Green VM: A DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 102: 19093-19096, 2005. (Pubitemid 43049571)
47. Kasahara Y, Tsukada Y. New insights and future advances in cancer diagnostics: Limitations of conventional tumor markers. In: Nakamura RM, Grody W, Wu JT, and Nagle RB, editors. Cancer Diagnostics: Current and future trends. Totowa, NJ: Humanna Press, pp. 15-26, 2004.
48. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG and Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998. (Pubitemid 28233009)
49. Harvei S, Skijorten FJ, Robsahm TE, Berner A and Tretli S: Is prostatic intraepithelial neoplasia in the transition/central zone a true precursor of cancer? A long-term retrospective study in Norway. Br J Cancer 78: 46-49, 1998. (Pubitemid 28276768)
50. Goeman L, Joniau S, Ponette D, Van der Aa F, Roskams T, Oyen R and Van Poppel H: Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer. Prostate Cancer Prostatic Dis 6: 305-310, 2003. (Pubitemid 38088193)
51. Joniau S, Goeman L, Pennings J and Van Poppel H: Prostatic intraepithelial neoplasia (PIN): importance and clinical managment. Eur Urol 48: 379-385, 2005. (Pubitemid 41188391)
52. Bostwick DG: Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 17: 187-189, 1999.
53. Haggman MJ, Adolfsson J, Khoury S, Montie JE and Norlen J: Clinical managment of premalignant lesions of the prostate. WHO Collaborative Project and Consensus Conference on Public Health and Clinical Significance of Premalignant Alterations in the Genitourinary Tract. Scand J Urol Nephol Suppl 205: 44-49, 2000.
54. Ashida S, Nakagawa H, Katagiri T, Furihata M, Liizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T and Nakamura Y: Molecular features of the transition from prostate intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene- expression profiles of prostate cancers and PINs. Cancer Res 64: 5963-5972, 2004. (Pubitemid 39129392)
55. Wamberg F, Nordgren H, Bergkvist L and Hulmberg L: Tumor markers in breast carcinomas correlate with grade rather than with invasiveness. Br J Cancer 85: 869-874, 2001. (Pubitemid 33010555)
56. Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, Aokage K, Yanagi S, Nagai K, Nishiwaki Y and Ochiai A: Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol 5: 1361-1368, 2010.
57. Leong KG and Gao WQ: The Notch pathway in prostate development and cancer. Differentiation 76: 699-716, 2008. (Pubitemid 352036647)
58. Villaronga MA, Bevan CL and Belandia B: Notch signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Targets 8: 566-580, 2008.
59. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B and Miele L: Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152, 2010.
60. Artavanis-Tsakonas S and Muskavitch MA: Notch: the past, the present, and the future. Curr Top Dev Biol 92: 1-29, 2010.
61. Lin SL, Chiang A, Chang D and Ying SY: Loss of miR-146a function in hormone-refractory prostate cancer. RNA 14: 417-424, 2008. (Pubitemid 351397806)
62. Xu B, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, Tong N, Wang JF, Song NH, Zhang W, Hua LX and Wu HF: A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 70: 467-472, 2010.
63. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A and Chopp M: MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 10: 1024-1030, 2010.
64. Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA and Daly RJ : Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2-docking protein. J Biol Chem 281: 626-631, 2006.
65. Oliveira AM, Ross JS and Fletcher JA: Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124(Suppl): S16-28, 2005.
66. Yanochko GM and Eckhart W: Type 1 insulin-like growth factor overexpression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res 8: 18-23, 2006.
67. Boulikas T: Control of DNA replication by protein phosphorylation. Anticancer Res 14: 2465-2472, 1994.
68. Boulikas T: Phosphorylation of transcription factors and control of the cell cycle. Crit Rev Eukaryot Gene Exp 5: 1-77, 1995.
69. Chakravarthy MV, Spangenhurg EE and Booth FW: Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. Cell Mol Life Sci 58: 1150-1158, 2001. (Pubitemid 32756525)
70. Csete M, Walikonis J, Slawny N, Wei Y, Korsnes S, Doyle JC and Wold B: Oxygen-mediated regulation of skeletal muscle satellite cell proliferation and adipogenesis in culture. J Cell Physical 189: 189-196, 2001. (Pubitemid 32946030)
71. Studer L, Csete M and Lee SH: Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowed oxygen. J Neurosci 20: 7377-7383, 2000.
72. Asano-kato N, Fukagawa K and Okada N: Tryptase increase proliferative activity of human conjunctive fibroblasts through protease-activated receptor. Invest Ophthalmol Vis Sci 46: 4622-4626, 2005. (Pubitemid 44264563)
73. Freeman MR, Schneck FX, Gognon ML, Corless C, Soker S, Niknejad K, Peoples GE and Klagsbrun M: Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelian1 growth factor: a potential role for T-cells in angiogenesis. Cancer Res 55: 4140-4145, 1995.
74. Nienartowicz A, Sobaniee-Lotowska ME, Jarocka-Cyrta E and Lemancewicz D: Mast cells in neoangiogenesis. Med Sci Monit 12: 53-56, 2006.
75. Qu Z: Immunohistological detection of growth factors and cytokines in tissue mast cells. Methods Mol Biol 315: 257-272, 2006.
76. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR and Ellis LM: Platelet-derived endothelial cell growth factor in human Colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88: 1146-1151, 1996. (Pubitemid 26274608)
77. Kang Y and Massague J: Epithelial-mesenchymal transition: twist in development and metastasis. Cell 118: 277-279, 2004. (Pubitemid 39061108)
78. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92: 47-56, 2004. (Pubitemid 38147370)
79. Strizzi L, Bianco C and Normanno N: Epithelial-mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Criptol-1 transgenic mice. J Cell Physiol 201: 266-276, 2004. (Pubitemid 39305104)
80. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN and Yu D: c-erbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 6: 2028-2037, 2006.
81. Carter WB, Hoying JB, Boswell C and Williams SK: HER2/neu overexpression induces endothelial cell retraction. Int J Cancer 91: 295-299, 2001. (Pubitemid 32049621)
82. Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, De Jongh GJ and Schalkwijk J: Tenascin expression in basal cell carcinoma. Brit J Dermt 127: 571-574, 1992.
83. Ilunga K, Nishiura R, Inada H, El-Karef A, Imanaka-Yoshida K, Sakakura T and Yoshida T: Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenasicin-c enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol 85: 373-379, 2004. (Pubitemid 39647366)